Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plexxikon has chosen Clinipace Worldwide, a digital clinical research organization (dCRO), for managing all aspects of its four clinical trials including Phase 1 healthy volunteer study, a Phase 1b rheumatoid arthritis (RA) study, and two Phase 2 oncology studies.
Subscribe to our email newsletter
Earlier in January 2011, Plexxikon has started patient recruitment in first of two Phase 1 clinical trials with PLX5622.
The initial Phase 1 trial is a single-ascending dose (SAD) study in up to 48 healthy volunteers.
The second trial is a multiple-ascending dose (MAD) study in approximately 32 RA patients that will begin once the first SAD healthy volunteer cohort has been cleared for safety, with continued enrollment in a staggered fashion following each SAD dose level.
Both studies are being managed by Clinipace Worldwide.
Plexxikon Business Development director said they chose Clinipace Worldwide to manage these important clinical trials for both PLX5622 and PLX3397 based on Clinipace’s commitment to customer service.